Form 4: Inmune Bio Reprices Director Stock Options to $1.50

Inmune Bio, Inc. has repriced certain outstanding stock options for Director Marcia Allen to an exercise price of $1.50 per share, reflecting the stock's closing price on November 18, 2025.

Summary

• Inmune Bio, Inc. (INMB) has completed a one-time repricing of certain outstanding stock options for Director Marcia Allen.
• The exercise price for these options has been reduced to $1.50 per share.
• This new exercise price matches the closing price of Inmune Bio's common stock on The Nasdaq Capital Market on the repricing date, November 18, 2025.
• A total of 258,000 stock options held by Marcia Allen were repriced.
• The repriced options were originally granted under the company's 2017, 2019, and 2021 Stock Incentive Plans with various higher exercise prices, including $3.91, $24.82, $17.49, $7.92, $9.74, $5.05, and $9.92.
• All other terms and conditions of the repriced options, including vesting schedules and term, remain unchanged.
• The repricing was approved by the Issuer's stockholders.

Sentiment

Score: 3

Explanation: The repricing of stock options, while potentially positive for option holders by restoring incentive, is a strong indicator of significant past stock underperformance. It suggests a substantial decline in market value, which is generally negative for existing shareholders and reflects poorly on the company's recent operational or financial results. The stockholder approval mitigates some governance concerns, but the underlying reason for the repricing remains a negative signal.

Positives

• The repricing makes the stock options significantly 'in-the-money' or closer to it for the option holder, potentially increasing their incentive and retention.
• Stockholder approval for the repricing indicates alignment between management and shareholders on this specific action.

Negatives

• The repricing of options to $1.50 from significantly higher prices (e.g., $24.82, $17.49, $9.92) indicates a substantial decline in the company's stock price since the original grant dates.
• This action dilutes existing shareholder value by effectively granting new options at a much lower strike price, potentially increasing the number of shares outstanding if exercised.
• Repricing can signal poor past performance or a lack of confidence in the near-term recovery of the stock price to previous levels.

Risks

• The underlying reason for the significant drop in stock price that necessitated the repricing could indicate ongoing business or operational risks not detailed in this specific filing.
• Potential for increased shareholder dilution if the repriced options are exercised, impacting earnings per share.
• Repricing options can sometimes be viewed negatively by investors as it may suggest a lack of accountability for past stock performance.

Future Outlook

The repriced stock options remain subject to their original vesting schedules, indicating that the company expects continued service from the reporting person and that these options will become exercisable over time, aligning incentives for future performance.

Management Comments

• "Effective as of November 18, 2025 (the 'Repricing Date'), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options... which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date."
• "Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."
• "This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."

Industry Context

Option repricing is a common practice in industries, particularly biotechnology or early-stage companies, where stock prices can be highly volatile due to clinical trial results, regulatory approvals, or funding rounds. When a company's stock price significantly declines, repricing options can be used to restore the incentive value of equity awards for employees and directors, preventing them from becoming 'underwater' and thus ineffective as retention tools. However, it also signals that the company's stock has underperformed significantly.

Comparison to Industry Standards

• Repricing underwater stock options is a practice seen across various industries, particularly in sectors with high volatility like biotech, where companies such as Moderna (MRNA) or BioNTech (BNTX) have experienced significant stock fluctuations.
• While it can re-incentivize management, it often contrasts with best practices for strong corporate governance, which typically favor performance-based awards that maintain their original strike price, similar to how established tech companies like Apple (AAPL) or Microsoft (MSFT) manage their equity compensation, where repricing is rare.
• The approval by stockholders is a positive governance step, but the necessity of repricing from prices as high as $24.82 to $1.50 suggests a performance gap compared to peers that maintain or grow their stock value over similar periods.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution from the repriced options and a signal of significant past stock price decline. While approved, it may raise questions about management accountability for stock performance.
• Employees/Directors (Option Holders): Increased incentive and retention as previously underwater options become valuable again, aligning their interests with future stock price recovery.

Next Steps

• The repriced options will become exercisable in accordance with their original vesting schedules, subject to Marcia Allen's continued service.

Key Dates

Recommendation

The repricing of stock options from significantly higher prices to $1.50 indicates a severe decline in the company's stock value, suggesting fundamental issues or significant underperformance. While the repricing aims to re-incentivize management, it effectively dilutes existing shareholder value and signals a lack of confidence in the stock's ability to recover to previous levels in the near term. This action, even with shareholder approval, is a strong negative indicator for the company's financial health and future prospects, warranting a "sell" recommendation for investors.

Keywords

Inmune Bio, INMB, Stock Options, Repricing, Form 4, SEC Filing, Corporate Governance, Director Compensation, Equity Incentive Plan, Nasdaq